[HTML][HTML] Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers

…, A Jary, K Dorgham, T Bruel, S Burrel… - Nature …, 2021 - nature.com
There are only few data concerning persistence of neutralizing antibodies (NAbs) among
SARS-CoV-2-infected healthcare workers (HCW). These individuals are particularly exposed …

Evidence of human-to-dog transmission of monkeypox virus

S Seang, S Burrel, E Todesco, V Leducq, G Monsel… - The Lancet, 2022 - thelancet.com
Human monkeypox virus is spreading in Europe and the USA among individuals who have
not travelled to endemic areas. 1 On July 23, 2022, monkeypox was declared a Public …

The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies

…, L Vidaur, SG Tangye, S Burrel… - Proceedings of the …, 2022 - National Acad Sciences
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection fatality rate (IFR)
doubles with every 5 y of age from childhood onward. Circulating autoantibodies neutralizing …

Autoantibodies neutralizing type I IFNs are present in~ 4% of uninfected individuals over 70 years old and account for~ 20% of COVID-19 deaths

…, M Tsumura, L Vidaur, SG Tangye, S Burrel… - Science …, 2021 - science.org
Circulating autoantibodies (auto-Abs) neutralizing high concentrations (10 ng/ml; in plasma
diluted 1:10) of IFN-α and/or IFN-ω are found in about 10% of patients with critical COVID-19 …

[HTML][HTML] Viral loads in clinical samples of men with monkeypox virus infection: a French case series

R Palich, S Burrel, G Monsel, A Nouchi… - The Lancet Infectious …, 2023 - thelancet.com
Background Monkeypox virus (MPXV) is currently spreading among men who have sex with
men, outside of sub-Saharan Africa, and close contact during sex seems to be one of the …

[HTML][HTML] Co-infection of SARS-CoV-2 with other respiratory viruses and performance of lower respiratory tract samples for the diagnosis of COVID-19

S Burrel, P Hausfater, M Dres, V Pourcher… - International Journal of …, 2021 - Elsevier
Objectives We performed a study during the early outbreak period of coronavirus disease
2019 (COVID-19) and the seasonal epidemics of other respiratory viral infections in order to …

Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs

…, NS Sharif-Askari, J Danielson, S Burrel… - Science …, 2023 - science.org
Life-threatening “breakthrough” cases of critical COVID-19 are attributed to poor or waning
antibody (Ab) response to SARS-CoV-2 vaccines in individuals already at risk. Preexisting …

[HTML][HTML] Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial

…, G Plantefève, S Malard-Castagnet, S Burrel… - Critical Care, 2022 - Springer
Background Severe acute respiratory syndrome coronavirus-2 (SARS–CoV-2)-induced
acute respiratory distress syndrome (ARDS) causes high mortality. Umbilical cord-derived …

[HTML][HTML] Ventilator-associated pneumonia in patients with SARS-CoV-2-associated acute respiratory distress syndrome requiring ECMO: a retrospective cohort study

CE Luyt, T Sahnoun, M Gautier, P Vidal, S Burrel… - Annals of Intensive …, 2020 - Springer
Background The data on incidence, clinical presentation, and outcomes of ventilator-associated
pneumonia (VAP) in patients with severe coronavirus disease 2019 (COVID-19) …

Resistance of herpes simplex viruses to acyclovir: an update from a ten-year survey in France

E Frobert, S Burrel, S Ducastelle-Lepretre, G Billaud… - Antiviral research, 2014 - Elsevier
The widespread use of acyclovir (ACV) and the increasing number of immunocompromised
patients have raised concern about an increase in ACV-resistant herpes simplex virus (HSV)…